Kong Ruina, Zhang Ju, Ji Lianmei, Yu Yiyi, Gao Jie, Zhao Dongbao
Department of Rheumatology and Immunology, The First Affiliated Hospital of Naval Medical University, No. 168 Changhai Road, Shanghai, 200433, China.
Inflammopharmacology. 2023 Apr;31(2):915-926. doi: 10.1007/s10787-023-01142-y. Epub 2023 Mar 2.
Our previous study revealed that synovial mesenchymal stem cell (SMSC)-derived exosomal microRNA-302c enhanced chondrogenesis by targeting a disintegrin and metalloproteinase 19 (ADAM19) in vitro. This study aimed to validate the potential of SMSC-derived exosomal microRNA-302c for the treatment of osteoarthritis in vivo.
After 4 weeks of destabilization of the medial meniscus surgery (DMM) to establish an osteoarthritis model, the rats received weekly articular cavity injection of SMSCs with or without GW4869 treatment (exosome inhibitor) or exosomes from SMSCs with or without microRNA-320c overexpression for another 4 weeks.
SMSCs and SMSC-derived exosomes reduced the Osteoarthritis Research Society International (OARSI) score, improved cartilage damage repair, suppressed cartilage inflammation, suppressed extracellular matrix (ECM) degradation, and inhibited chondrocyte apoptosis in DMM rats. However, these effects were largely hampered in rats that were injected with GW4869-treated SMSCs. Moreover, exosomes from microRNA-320c-overexpressing SMSCs exerted a better effect than exosomes from negative control SMSCs on decreasing the OARSI score, enhancing cartilage damage repair, suppressing cartilage inflammation, and inhibiting ECM degradation and chondrocyte apoptosis. Mechanistically, exosomes from microRNA-320c-overexpressing SMSCs reduced the levels of ADAM19, as well as β-catenin and MYC, which are two critical proteins in Wnt signalling.
SMSC-derived exosomal microRNA-320c suppresses ECM degradation and chondrocyte apoptosis to facilitate cartilage damage repair in osteoarthritis rats by targeting ADAM19-dependent Wnt signalling.
我们之前的研究表明,滑膜间充质干细胞(SMSC)来源的外泌体微RNA-302c在体外通过靶向解整合素和金属蛋白酶19(ADAM19)增强软骨生成。本研究旨在验证SMSC来源的外泌体微RNA-302c在体内治疗骨关节炎的潜力。
在进行内侧半月板手术(DMM)失稳4周以建立骨关节炎模型后,大鼠每周接受关节腔注射SMSC,其中部分SMSC经过或未经过GW4869处理(外泌体抑制剂),或者注射来自SMSC的外泌体,部分外泌体经过或未经过微RNA-320c过表达处理,持续4周。
SMSC和SMSC来源的外泌体降低了国际骨关节炎研究学会(OARSI)评分,改善了软骨损伤修复,抑制了软骨炎症,抑制了细胞外基质(ECM)降解,并抑制了DMM大鼠软骨细胞凋亡。然而,在注射了经GW4869处理的SMSC的大鼠中,这些作用在很大程度上受到阻碍。此外,来自微RNA-320c过表达SMSC的外泌体在降低OARSI评分、增强软骨损伤修复、抑制软骨炎症以及抑制ECM降解和软骨细胞凋亡方面,比来自阴性对照SMSC的外泌体发挥了更好的作用。从机制上讲,来自微RNA-320c过表达SMSC的外泌体降低了ADAM19以及β-连环蛋白和MYC的水平,这两种是Wnt信号通路中的关键蛋白。
SMSC来源的外泌体微RNA-320c通过靶向ADAM19依赖的Wnt信号通路,抑制ECM降解和软骨细胞凋亡,促进骨关节炎大鼠的软骨损伤修复。